Characteristics of patients included in the NHL-B2 trial
. | All, % . | CHOP-21, % . | CHOP-14, % . | CHOP-21, % . | CHOEP-14, % . | P . |
|---|---|---|---|---|---|---|
| Age, y | .004 | |||||
| 61-65 | 40.6 | 40.4 | 37.8 | 51.2 | 33.1 | |
| 66-70 | 37.0 | 42.1 | 38.4 | 25.3 | 42.0 | |
| 71-75 | 22.4 | 17.4 | 23.8 | 23.5 | 24.9 | |
| Sex | .368 | |||||
| Male | 50.9 | 51.7 | 46.5 | 55.9 | 49.7 | |
| Female | 49.1 | 48.3 | 53.5 | 44.1 | 50.3 | |
| LDH greater than normal | 45.9 | 46.1 | 45.9 | 44.7 | 46.7 | .986 |
| Performance status | ||||||
| ECOG | .400 | |||||
| 0 | 44.0 | 42.1 | 48.3 | 48.2 | 37.3 | |
| 1 | 37.9 | 38.8 | 33.1 | 38.2 | 41.4 | |
| 2 | 14.1 | 13.5 | 15.1 | 10.6 | 17.2 | |
| 3 | 4.1 | 5.6 | 3.5 | 2.9 | 4.1 | |
| More than 1 | 18.1 | 19.1 | 18.6 | 13.5 | 21.3 | .295 |
| Extranodal sites | .233 | |||||
| No | 43.4 | 41.6 | 47.7 | 46.5 | 37.9 | |
| Yes | 56.6 | 58.4 | 52.3 | 53.5 | 62.1 | |
| More than 1 | 25.0 | 30.9 | 18.6 | 22.4 | 27.8 | .038 |
| Stage | .154 | |||||
| I | 16.4 | 10.1 | 22.7 | 16.5 | 16.6 | |
| II | 32.8 | 36.5 | 27.9 | 34.1 | 32.5 | |
| III | 26.3 | 25.8 | 29.1 | 24.7 | 25.4 | |
| IV | 24.5 | 27.5 | 20.3 | 24.7 | 25.4 | |
| III/IV | 50.8 | 53.4 | 49.4 | 49.4 | 50.9 | .865 |
| Bulky disease, 7.5 cm or larger | 39.2 | 39.9 | 37.8 | 38.8 | 40.2 | .966 |
| Bone marrow involvement | 11.6 | 12.9 | 11.6 | 10.0 | 11.8 | .865 |
| B symptoms | 36.7 | 42.1 | 40.7 | 32.9 | 30.8 | .071 |
| IPI | .556 | |||||
| 1 | 29.2 | 28.7 | 30.8 | 30.6 | 26.6 | |
| 2 | 27.3 | 24.2 | 27.3 | 30.6 | 27.2 | |
| 3 | 23.4 | 21.9 | 25.6 | 22.4 | 23.7 | |
| 4, 5 | 20.2 | 25.3 | 16.3 | 16.5 | 22.5 |
. | All, % . | CHOP-21, % . | CHOP-14, % . | CHOP-21, % . | CHOEP-14, % . | P . |
|---|---|---|---|---|---|---|
| Age, y | .004 | |||||
| 61-65 | 40.6 | 40.4 | 37.8 | 51.2 | 33.1 | |
| 66-70 | 37.0 | 42.1 | 38.4 | 25.3 | 42.0 | |
| 71-75 | 22.4 | 17.4 | 23.8 | 23.5 | 24.9 | |
| Sex | .368 | |||||
| Male | 50.9 | 51.7 | 46.5 | 55.9 | 49.7 | |
| Female | 49.1 | 48.3 | 53.5 | 44.1 | 50.3 | |
| LDH greater than normal | 45.9 | 46.1 | 45.9 | 44.7 | 46.7 | .986 |
| Performance status | ||||||
| ECOG | .400 | |||||
| 0 | 44.0 | 42.1 | 48.3 | 48.2 | 37.3 | |
| 1 | 37.9 | 38.8 | 33.1 | 38.2 | 41.4 | |
| 2 | 14.1 | 13.5 | 15.1 | 10.6 | 17.2 | |
| 3 | 4.1 | 5.6 | 3.5 | 2.9 | 4.1 | |
| More than 1 | 18.1 | 19.1 | 18.6 | 13.5 | 21.3 | .295 |
| Extranodal sites | .233 | |||||
| No | 43.4 | 41.6 | 47.7 | 46.5 | 37.9 | |
| Yes | 56.6 | 58.4 | 52.3 | 53.5 | 62.1 | |
| More than 1 | 25.0 | 30.9 | 18.6 | 22.4 | 27.8 | .038 |
| Stage | .154 | |||||
| I | 16.4 | 10.1 | 22.7 | 16.5 | 16.6 | |
| II | 32.8 | 36.5 | 27.9 | 34.1 | 32.5 | |
| III | 26.3 | 25.8 | 29.1 | 24.7 | 25.4 | |
| IV | 24.5 | 27.5 | 20.3 | 24.7 | 25.4 | |
| III/IV | 50.8 | 53.4 | 49.4 | 49.4 | 50.9 | .865 |
| Bulky disease, 7.5 cm or larger | 39.2 | 39.9 | 37.8 | 38.8 | 40.2 | .966 |
| Bone marrow involvement | 11.6 | 12.9 | 11.6 | 10.0 | 11.8 | .865 |
| B symptoms | 36.7 | 42.1 | 40.7 | 32.9 | 30.8 | .071 |
| IPI | .556 | |||||
| 1 | 29.2 | 28.7 | 30.8 | 30.6 | 26.6 | |
| 2 | 27.3 | 24.2 | 27.3 | 30.6 | 27.2 | |
| 3 | 23.4 | 21.9 | 25.6 | 22.4 | 23.7 | |
| 4, 5 | 20.2 | 25.3 | 16.3 | 16.5 | 22.5 |
Patient populations are as follows: all, N = 689; CHOP-21, n = 178; CHOP-14, n = 172; CHOEP-21, n = 170; and CHOEP-14, n = 169.